CX 1739 - RespireRx

Drug Profile

CX 1739 - RespireRx

Alternative Names: CX-1739

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cortex Pharmaceuticals
  • Developer Cortex Pharmaceuticals; National Institute on Drug Abuse; RespireRx Pharmaceuticals
  • Class Antidementias; Mood stabilisers; Respiratory stimulants
  • Mechanism of Action AMPA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Respiratory insufficiency; Sleep apnoea syndrome
  • Preclinical Drug abuse
  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 06 Sep 2017 RespirRx plans a clinical trial in Respiratory insufficiency
  • 14 Jun 2017 RespireRx intends to file an IND, and initiate a phase II trial investigating the ability of CX 1739 to reduce central sleep apnoea in patients taking chronic opioids
  • 06 Jan 2017 RespireRx Pharmaceuticals plans a phase II trial Sleep apnoea syndrome (Opioid induced)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top